92 related articles for article (PubMed ID: 1654194)
1. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.
Büchler M; Friess H; Schultheiss KH; Gebhardt C; Kübel R; Muhrer KH; Winkelmann M; Wagener T; Klapdor R; Kaul M
Cancer; 1991 Oct; 68(7):1507-12. PubMed ID: 1654194
[TBL] [Abstract][Full Text] [Related]
2. Studies of pancreatic cancer utilizing monoclonal antibodies.
Büchler M; Friess H; Malfertheiner P; Schultheiss KH; Muhrer KH; Kraemer HP; Beger HG
Int J Pancreatol; 1990; 7(1-3):151-7. PubMed ID: 1964470
[TBL] [Abstract][Full Text] [Related]
3. [Monoclonal antibodies in the therapy of non-resectable pancreatic cancers. Initial experiences].
Muhrer KH; Büchler M; Lucks A; Süss D; Klapdor R; Schulz G
Chirurg; 1988 May; 59(5):328-34. PubMed ID: 3396446
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary results of cytotoxic monoclonal antibody treatment in pancreatic adenocarcinomas and biliary tract carcinomas].
Leborgne J; Douillard JY; Kremer M
Ann Chir; 1990; 44(5):338-41. PubMed ID: 2372194
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494.
Schulz G; Büchler M; Muhrer KH; Klapdor R; Kübel R; Harthus HP; Madry N; Bosslet K
Int J Cancer Suppl; 1988; 2():89-94. PubMed ID: 3162451
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Morak MJ; van der Gaast A; Incrocci L; van Dekken H; Hermans JJ; Jeekel J; Hop WC; Kazemier G; van Eijck CH
Ann Surg; 2008 Dec; 248(6):1031-41. PubMed ID: 19092348
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
[TBL] [Abstract][Full Text] [Related]
9. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].
Büchler M; Kübel R; Malfertheiner P; Friess H; Schulz G; Bosslet K; Beger HG
Dtsch Med Wochenschr; 1988 Mar; 113(10):374-80. PubMed ID: 3349938
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers.
Friess H; Gassmann M; Büchler MW
Int J Pancreatol; 1997 Feb; 21(1):43-52. PubMed ID: 9127173
[TBL] [Abstract][Full Text] [Related]
12. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study.
Lygidakis NJ; Sgourakis G; Georgia D; Vlachos L; Raptis S
Ann Surg; 2002 Dec; 236(6):806-13. PubMed ID: 12454519
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer.
Nishihara T; Sawada T; Yamamoto A; Yamashita Y; Ho JJ; Kim YS; Chung KH
Jpn J Cancer Res; 2000 Aug; 91(8):817-24. PubMed ID: 10965023
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
[TBL] [Abstract][Full Text] [Related]
15. Role of surgery in ductal carcinoma of the pancreas.
Cangemi V; Volpino P; Mingazzini P; Fiori E; Gentili S; Ansali A; Piat G
Int Surg; 1992; 77(3):158-63. PubMed ID: 1328103
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of pancreatic carcinoma with the monoclonal antibody BW 494/32: first clinical results].
Friess H; Büchler M; Schulz G; Beger HG
Immun Infekt; 1989 Feb; 17(1):24-6. PubMed ID: 2925220
[TBL] [Abstract][Full Text] [Related]
17. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects.
Tempero MA; Sivinski C; Steplewski Z; Harvey E; Klassen L; Kay HD
J Clin Oncol; 1990 Dec; 8(12):2019-26. PubMed ID: 2121912
[TBL] [Abstract][Full Text] [Related]
19. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
20. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
